Evidence map›Paper›PMID 42005246›Full record

ReviewCureus2026

COVID-19-Associated Cardiovascular Complications: A Narrative Literature Review.

Aashna Lala, Mykhailo Vysochyn, Kateryna Shyshkova

Abstract readReview
In one paragraph

Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aashna LalaClinical Sciences, Saint James School of Medicine, Park Ridge, USA.
Mykhailo VysochynBasic Sciences, Saint James School of Medicine, Arnos Vale, VCT.
Kateryna ShyshkovaBasic Sciences, Saint James School of Medicine, Arnos Vale, VCT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, coronavirus disease 2019 (COVID-19) has caused significant global morbidity and mortality. Although initially recognized as a respiratory illness, COVID-19 is now understood to be a systemic disease with substantial cardiovascular involvement. Both patients with pre-existing cardiovascular disease and those without prior cardiac conditions may develop a wide range of cardiovascular complications during and after acute infection. Reported complications include myocardial injury, myocarditis, heart failure, arrhythmias, and thromboembolic events, all of which contribute to increased disease severity and mortality. This narrative review summarizes current evidence on cardiovascular complications associated with COVID-19 among adult patients in the United States, with particular attention to differences between individuals with pre-existing cardiovascular disease and those who develop new cardiovascular pathology following SARS-CoV-2 infection. This review discusses proposed mechanisms of cardiovascular injury, clinical manifestations, diagnostic approaches, and current management strategies. By summarizing current knowledge, this review aimed to increase awareness of COVID-19-related cardiovascular complications, support timely recognition in emergency and inpatient settings, and assist clinicians in improving patient outcomes.

Indexed as

cardiac arrhythmiascardiovascular complicationscovid-19heart failurehypercoagulabilityhypertensionmyocardial injurymyocarditissars-cov-2thromboembolism

Identifiers

PMID42005246
PMCPMC13086455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.